Measuring function, not just flora: why gut biomarker testing delivers deeper clinical insight

Testing gut biomarkers such as calprotectin, pancreatic elastase, and intestinal permeability markers provides more directly actionable insights into gut physiology and pathology than microbiome sequencing tests. While microbiome analysis maps microbial diversity and disease associations, biomarker testing reveals real-time functional and inflammatory processes that translate into clearer nutritional and clinical guidance.

Calprotectin: objective gut inflammation assessment

Calprotectin is a neutrophil-derived protein and a specific marker of intestinal inflammation, used clinically to differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS). Unlike microbial composition data, which indicates potential disease associations but not causation, faecal calprotectin levels directly quantify mucosal immune activation. Elevated readings correlate with increased cytokine production, intestinal permeability disruptions, and active mucosal damage — offering quantifiable evidence of inflammation that guides intervention and tracks response to dietary or therapeutic changes.

Pancreatic elastase: functional digestive status

Pancreatic elastase provides a functional measure of pancreatic exocrine output, which cannot be inferred from a microbiome test. Stool concentrations below 200 µg/g strongly suggest exocrine pancreatic insufficiency, a cause of fat malabsorption, dysbiosis, and nutrient deficiencies. Identifying this deficit directs practitioners toward targeted digestive enzyme support, testing for nutrient deficiencies such as iron, and personalised dietary and lifestyle strategies, leading to measurable improvements in nutrient absorption and gut microbial stability.

Microbiome sequencing may reveal bacterial signatures consistent with maldigestion, but elastase quantification data provide diagnostic precision and treatment guidance.

Intestinal permeability: barrier integrity and systemic effects

Permeability testing — using markers such as alpha1-antitrypsin or lactulose/mannitol — reflects the functional integrity of the epithelial barrier. Increased intestinal permeability ("leaky gut") allows microbial products to translocate into circulation, driving systemic inflammation and immune dysregulation. Measuring permeability can reveal early disruptions in mucosal health before chronic inflammation or autoimmune responses develop.

Current evidence indicates that faecal α₁-antitrypsin offers a far more reliable, standardised, and clinically interpretable measure of mucosal barrier dysfunction compared to zonulin which has gained attention as a proposed regulator of intestinal tight junctions. Unlike zonulin, A1AT reflects the actual translocation of plasma proteins across the intestinal barrier, providing a direct functional index of gut permeability rather than an indirect surrogate of tight junction signalling.

Whilst certain bacterial profiles are associated with dysbiosis and barrier dysfunction, microbiome testing alone cannot confirm epithelial compromise or measure the degree of paracellular leak.

Microbiome testing: associative but not diagnostic

Microbiome testing uses 16S rRNA or metagenomic sequencing to analyse gut microbiome profiles and estimate diversity, but this approach remains largely correlative. Even advanced microbiome analyses, such as those developed by ZOE and other research initiatives, acknowledge they can show links but not causation between microbial composition and disease.

Studies continue to show microbiome patterns associated with disease states like IBD or metabolic disorders, yet translating these findings into personalized interventions remains challenging due to interindividual variability, sequencing bias, and the dynamic nature of the microbiome.

Why biomarkers provide deeper clinical insight

In contrast, gut biomarkers deliver direct physiological readouts:

Together, they portray cause–effect mechanisms in gut dysfunction rather than associative microbial trends. These metrics are immediately interpretable, reproducible, and aligned with established clinical standards — offering nutrition practitioners specific, actionable insights for personalised care, dietary modification, and progress monitoring.

While microbiome testing illuminates microbial ecology, biomarker testing measures host response, bridging the gap between microbiota composition and actual functional gut health.

Enhancing clinical insights and personalised intervention through functional gut metrics and diet related immune response analysis.

Gut biomarker testing for inflammation (Calprotectin) digestive efficiency (pancreatic elastase), and intestinal permeability offers nutrition practitioners actionable insights by directly measuring physiological functions and pathological states affecting gut health. Calprotectin quantifies intestinal inflammation, helping differentiate inflammatory conditions from functional disorders. Pancreatic elastase assesses exocrine pancreatic function, indicating digestive enzyme sufficiency and guiding digestive enzyme support therapy if needed. Intestinal permeability markers reveal the integrity of the gut barrier, identifying “leaky gut” that can trigger systemic inflammation.

When combined with food IgG testing, which detects immune responses to specific foods suggesting sensitivities or intolerances, practitioners gain a comprehensive picture of gut health drivers, including delayed response diet related immune activation. This integrated approach empowers personalised, targeted dietary and therapeutic interventions, improving patient outcomes by addressing inflammation, digestion, barrier function, and food-related IgG immune triggers simultaneously.

Unlike microbiome tests that mainly profile gut microbial composition and associations, gut biomarker and IgG tests provide functional, mechanistic data that directly support clinical decision-making and monitoring over time.​

References